Journal article · 2023 · Open access

Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022

Oriana Ciani, Michela Meregaglia, Mario Alberto Battaglia, Gianpaolo Brichetto, Antonella Conte, Claudio Gasperini, Valeria Sansone

Neurological Sciences, 44(8), 2933–2937 · Published 5 May 2023 · DOI 10.1007/s10072-023-06825-6

Open PDFView at the publisherCite this paper

In brief

“Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022” is a 2023 journal article by Oriana Ciani and 6 co-authors, published in Neurological Sciences. OpenAlex counts 14 citations as of 22 November 2026, which puts it in the top 6% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Neurological Sciences.

Citations
14
Most cited in
2025 (8)
Field-weighted impact
2.05
References
8
Authors
7

Abstract

BACKGROUND: Regulatory agencies have been responsive to public demand for inclusion of the patient experience in evaluating and approving therapies. Over the years, patient-reported outcome measures (PROMs) have become increasingly prevalent in clinical trial protocols; however, their influence on regulators, payers, clinicians, and patients' decision-making is not always clear. We recently conducted a cross-sectional study aimed at investigating the use of PROMs in new regulatory approvals of drugs for neurological conditions between 2017 and 2022 in Europe. METHODS: We reviewed European Public Assessment Reports (EPARs) and recorded on a predefined data extraction form whether they considered PROMs, their characteristics (e.g., primary/secondary endpoint, generic/specific instrument) and other relevant information (e.g., therapeutic area, generic/biosimilar, orphan status). Results were tabulated and summarized by means of descriptive statistics. RESULTS: Of the 500 EPARs related to authorized medicines between January 2017 and December 2022, 42 (8%) concerned neurological indications. Among the EPARs of these products, 24 (57%) reported any use of PROMs, typically considered as secondary (38%) endpoints. In total, 100 PROMs were identified, of which the most common were the EQ-5D (9%), the SF-36 (6%), or its shorter adaptation SF-12, the PedsQL (4%). CONCLUSIONS: Compared to other disease areas, neurology is one where the use of patient-reported outcomes evidence is inherently part of the clinical evaluation and for which core outcome sets exist. Better harmonization of the instruments recommended for use would facilitate the consideration of PROMs at all stages in the drug development process.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ciani, O., Meregaglia, M., Battaglia, M. A., Brichetto, G., Conte, A., Gasperini, C., & Sansone, V. (2023). Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022. Neurological Sciences, 44(8), 2933–2937. https://doi.org/10.1007/s10072-023-06825-6

MLA 9

Ciani, Oriana, et al. “Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022.” Neurological Sciences, vol. 44, no. 8, 2023, pp. 2933–2937. https://doi.org/10.1007/s10072-023-06825-6.

Chicago

Ciani, Oriana, Michela Meregaglia, Mario Alberto Battaglia, Gianpaolo Brichetto, Antonella Conte, Claudio Gasperini, and Valeria Sansone. 2023. “Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022.” Neurological Sciences 44 (8): 2933–2937. https://doi.org/10.1007/s10072-023-06825-6.

Harvard

Ciani, O. et al. (2023) ‘Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022’, Neurological Sciences, 44(8), pp. 2933–2937. doi:10.1007/s10072-023-06825-6.

IEEE

O. Ciani et al., “Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022,” Neurological Sciences, vol. 44, no. 8, pp. 2933–2937, 2023, doi: 10.1007/s10072-023-06825-6.

BibTeX

@article{ciani2023patient,
  title     = {{Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022}},
  author    = {Ciani, Oriana and Meregaglia, Michela and Battaglia, Mario Alberto and Brichetto, Gianpaolo and Conte, Antonella and Gasperini, Claudio and Sansone, Valeria},
  journal   = {Neurological Sciences},
  year      = {2023},
  volume    = {44},
  number    = {8},
  pages     = {2933--2937},
  doi       = {10.1007/s10072-023-06825-6},
  url       = {https://doi.org/10.1007/s10072-023-06825-6}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202433
202588
202633

Its field-weighted citation impact is 2.05: it has been cited 2.05 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • patient-reported outcome measures
  • European Public Assessment Reports
  • drug approval
  • neurological disorders
  • EQ-5D
  • SF-36
  • PedsQL
  • core outcome set

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Ciani, O., Meregaglia, M., Battaglia, M. A., Brichetto, G., Conte, A., Gasperini, C., & Sansone, V. (2023). Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022. Neurological Sciences, 44(8), 2933–2937. https://doi.org/10.1007/s10072-023-06825-6

How many times has this paper been cited?

14 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Neurological Sciences: sign in and open the PDF from this page.

Who wrote this paper?

Oriana Ciani, Michela Meregaglia, Mario Alberto Battaglia, Gianpaolo Brichetto, Antonella Conte, Claudio Gasperini, Valeria Sansone.

What is the DOI of this paper?

10.1007/s10072-023-06825-6, permanently at https://doi.org/10.1007/s10072-023-06825-6. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.